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In recent years the combination of chemo and/or radiation therapy
before surgery has been investigated to prolong survival in
patients with squamous cell carcinoma of the oesophagus, but the
value of neoadjuvant therapy is currently under debate. In addition
to improved surgical resection of primary tumours with adequate
lymphadenectomy, preoperative radio/chemotherapy of advanced
tumours was another assumption to be locally free of tumour. The
lymphadenectomy was especially beneficial in patients with early
lymph node metastasis and in subgroups of patients with known
lymph node metastasis. With the help of neoadjuvant
radio/chemotherapy, the prolongation of entire and disease-free
survival could be achieved through preoperative reduction of the
primary tumour (Ajani, 1996; Siewert and Roder, 1992; Walsh
et al, 1996). Besides the possibility of complete tumour resection,
the neoadjuvant therapy could also minimize intraoperative
spreading of tumour cells and systemically treat potential existing
micrometastases (Herskovic et al, 1992; Siewert et al, 1996).
In spite of the optimized therapy techniques, tumour recurrence
occurs in nearly half of all patients with epithelial tumour of the
upper gastrointestinal tract within 5 years after initial surgery
(Bolton et al, 1996; Law et al, 1996). One reason may be that
previously available diagnostic techniques could not detect the
dissemination of micrometastatic cells in bone marrow, blood or
lymph nodes at the time of surgery. Recently, more sensitive
immunocytochemical and molecular methods were developed to
detect epithelial cells disseminated into secondary organs (Funke
and Schraut, 1998; Johnson et al, 1995; Pantel et al, 1993;
Riethmüller and Johnson, 1992). Patients with solid tumours in
which epithelial cells were found in bone marrow, despite
complete resection of the primary tumour, showed tumour recur-
rence more frequently throughout the course of disease than
patients in which cytokeratin (CK)-positive cells were not found
(Lindemann et al, 1992; Moss et al, 1991; Pantel et al, 1993). The
question remains, at which time-point does systemic metastasiza-
tion of oesophageal cancer begin? A possible improvement in
tumour staging and in identification of patients with risk of devel-
opment of tumour recurrence is the demonstration of epithelial
cells in bone marrow. The purpose of this prospective study was to
examine immunocytochemical epithelial cells in bone marrow of
patients with squamous cell carcinoma of the oesophagus. Using a
multivariate analysis we determine the role of CK-positive cells in
bone marrow at the time of first diagnosis in the prognosis of these
patients.
MATERIALS AND METHODS
Patients and study design
Between August 1992 and December 1997, a total of 225 patients
with histologically proven squamous cell carcinoma of the
oesophagus were prospectively admitted and operated upon at our
institute. From these 225 patients, 75 agreed to participate in the
study. Thirty-eight (59.7%) of the 75 patients were initially
operated, while 37 (49.3%) patients underwent neoadjuvant
radio/chemotherapy prior to surgery. Patient characteristics are
shown in Table 1. In these patients, either tumour resection was
initially intended or in cases in which the locally advanced tumour
extended beyond the organ, neoadjuvant radio/chemotherapy prior
to resection of the primary tumour was performed. Besides a
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the clarification of functional operability was essential for the
selection of treatment. Therefore, for each patient a preoperative
risk score was assigned in order to objectively determine
pulmonary, cardiac, liver and kidney function, as well as coopera-
tiveness, general status (Karnofsky Index > 70%), and bone
marrow function. In order to obtain exact preoperative tumour
staging, endoscopy and endosonography were under taken for
histological biopsies and determination of T-category of the
tumour. Furthermore, depending on the condition of the primary
tumour, computerized tomography of the neck, chest, or abdomen
was performed. The examination was completed with upper
abdomen sonography and skeletal scintigraphy to rule out remote
metastases (Dittler and Siewert, 1993; Fink et al, 1995). Exclusion
criteria for surgery or neoadjuvant therapy included Karnofsky
index > 70%, life expectancy less than 3 months, tumour bleeding,
secondary tumours, remote metastases, liver cirrhosis, manifest
alcohol abuse, peritoneal carcinosis or other remote metastases.
The selection of therapy was performed dependently of the
resectability of the primary tumour and the overall status of the
patient. Surgery-only option was always indicated in cases in
which the tumour appears to be completely respectable and it was
allowed by the overall status of the patient. In patients with locally
advanced tumours and questionable curative resection possibility,
the multi-modality concept with preoperative radio/chemotherapy
was employed. For the documentation of comparability and repre-
sentativeness of the examined patients, all patients with surgery
and all patients with neoadjuvant therapy from the study were
compared to the total patient population. Age, gender, primary
tumour status, and RO-resection quota using the Mann-Whitney
test were comparable between the two groups. Total survival time
was also not significantly different in the operated patients and the
neoadjuvant pretreated patients compared to total patients.
Bone marrow aspiration and immunocytochemistry
After approval of the study by our ethics committee and oral as
well written informed consent from the patients, a standardized
bone marrow puncture was performed in all patients prior to the
start of therapy. The punctures at the iliac spine (anterior superior
or posterior superior) were performed either under local anaes-
thesia or during general anaesthesia at the beginning of the
surgery. 2–5 ml bone marrow was obtained and all specimens 
from a given individual were pooled before further processing.
Mononuclear cells (MNCs) were isolated by density-gradient
centrifugation by Ficoll-Hypaque (Pharmacia Freiburg, Germany)
at 400 g for 30 min at room temperature and then deposited onto
glass slides by cytocentrifugation at 150 g for 8 min, also at room
temperature. The number of MNCs spun onto each slide was
2 ´ 106. The cytocentrifuge preparations were fixed with acetone
for 10 min at room temperature, airdried, and then preincubated
with antibody-free human serum for 25 min to block non-specific
antibody binding. Epithelial cells were identified using the mouse
antocytokeratin monoclonal antibody (MAb) A-45-B/B3, which
detects a common epitope present on a variety of cytokeratin
components, including cytokeratins 8,18 and 19. The MAb was
applied at optimum concentration, ranging from 2–5 mg ml–1, for
45 min at room temperature. For visualization of antibody
binding, the sensitive alkaline phosphatase anti-alkaline phos-
phatase technique (APAAP) was employed (Lindemann et al,
1992; Pantel et al, 1993). Alkaline phosphatase activity was moni-
tored by use of the Neufuchsin stain, and endogenic formation of
phosphatase activity was blocked by preincubation with
levamisole. The relative proportion of positive cells was recorded
quantitatively, differentiating between single cells and cell clus-
ters. For each patient, five slides containing a total of 2 ´ 106
MNCs were evaluated by two independent observers in a double-
blinded fashion. The specifity of the MAbs as epithelial marker
proteins in the bone marrow of patients with solid tumours could
additionally be confirmed by examination in 35 disease-free
patients of the control group. This control patient group did not
differ significantly from the total patient population with respect to
gender and age. False-positive immunocytochemical colour reac-
tion with the above-mentioned mAb was not found in any of these
patients.
Surgical and neoadjuvant therapy
All patients with primary resectable squamous cell carcinoma of
the oesophagus underwent a one-time transthoracic en-bloc
oesophagectomy. After a right thoracotomy, the resection of the
oesophagus together with the mediastinal lymph nodes was
performed. The reconstruction of the oesophagus was performed
through the abdominal and left cervical access either by an upward
displacement of the stomach or, where the stomach could not 
be used due to preoperative or accompanying disease, it was
performed by a colon interposition. Patients with locally advanced
tumours without remote metastases (stage III, T3,N1,MO) under-
went neoadjuvant therapy and then oesophagectomy in two
sessions. Four weeks after the end of the radio/chemotherapy
through transthoracic surgery the oesophagectomy with
lymphadenectomy was performed. Then, 3–4 weeks later, recon-
struction was performed in the anterior mediastinum. The preoper-
ative radio/chemotherapy consisted of one cycle of fluorouracil
(300 mg m–2, given as continuous infusion during radiation
therapy) and 3000 cGy (Rad) radiation dose over 3 weeks in 15
sessions Of 200 cGy per day, 5 days per week (Anderson and Lad,
1982; Brockmeyer and Crowley, 1982; Law et al, 1996).
36 S Thorban et al
British Journal of Cancer (2000) 83(1), 35–39 © 2000 Cancer Research Campaign
Table 1 Characteristics of the patients and primary tumour stage (number
of patients (%))
All patients Study patients
(n = 225) (n = 75)
Male 178 (79.1) 65 (86.7)
Female 47 (20.9) 10 (13.3)
Age (range) 59.3 (22–81) 55.5 (34–72)
Therapy
Tumour resection 125 (55.6) 38 (50.7)
Preop. RTx/CTx and 100 (44.4) 37 (49.3)
tumour resection
Tumour stage
Stage I 47 (20.9) 18 (24.0)
Stage IIa 61 (27.1) 18 (24.0)
Stage IIb 22 (9.8) 8 (10.7)
Stage III 64 (28.4) 29 (38.7)
Stage IV 31 (13.8) 2 (2.7)
R-category
RO-resection 169 (75.1) 59 (78.7)
R1/2-resection 56 (24.9) 16 (21.3)
RTx/CTx = preoperative radio-/chemotherapy; Ro-resection = curative
resection without microscopic/macroscopic residual tumour;
R1/2-resection = microscopic and macroscopic residual tumourData evaluation
The immunocytochemical determined count of epithelial cells in
bone marrow of all patients were correlated with established
patient-specific and histopathologic prognosis factors (Table 2).
Tumour follow-up examinations in the first postoperative year at
3, 6, and 12 months, then every year, were performed by our
oncology outpatient unit or by the family physician. In addition to
evaluation of clinical symptoms including loss of weight or
changes in general status. these examinations consisted of ultra-
sound examination, as well as X-ray examination, computer-
tomography of the chest and abdominal wall and bone scanning
for early detection of local recurrence or remote metastases. If
there was evidence for tumour recurrence, histological verification
was attempted.
The documentation of the patient data was performed according
to a standardized study protocol, which was planned and designed
under the statistical advice of the Institute for Medical Statistics
and Epidemology of the Technischen Universität München.
Statistical analysis was performed using a BMDP software
package (BMDP Statistical Software Inc., Los Angeles, USA).
The survival curve with a 95% confidence interval was calculated
from the Kaplan-Meler and Brookmeyer method (Brockmeyer and
Crowley, 1982; Kaplan and Meier, 1958). Differences between
each patient group were determined using the Log rank test.
The significance was determined using the Mann-Whitney and
Chi-Square test, in which P < 0.05 was considered as statistically
significant. All statistical calculations were performed for the total
patient population of the study, and also for the subgroup of
patients with curative (RO) resection. For the primary tumour
staging and classification of the TNM-category the UICC-
classification from 1997 was used (Wittekind and Wagner, 1997).
RESULTS
Incidence and frequency of epithelial cells
Altogether, 29 of 75 (38.7%) patients with squamous cell carci-
noma of the oesophagus showed CK-positive cells in bone
marrow. In 21 (72.4%) of these positive bone marrow samples,
less than 10 cells per 2 ´ 106 examined MNCs were found. The
majority of the patients had few epithelial cells, while clusters of
CK-positive cells were found in only 8 (27.6%) of the patients.
Significant differences with regard to recurrent rate and total
survival time between patients with few epithelial cells, compared
to patients with cell clusters in bone marrow, were not found.
Survival and tumour recurrence
Within the median follow-up period of 35.7 months (3–61
months), the analyses of the mean and median overall survival
time showed a significant difference between patients with and
without detection of CK-positive bone marrow (P < 0.001, Figure
1). Of the 59 patients with RO-resection, 16 (72.7%) of the 
CK-positive patients and only four (10.8%) of the CK-negative
patients developed tumour recurrence during the follow-up period.
In eight CK-positive patients, tumour recurrence was found with
remote metastases (lung two, liver two, skeletal one, peritoneal
one). In another eight patients local recurrence of tumour was
observed. Regarding CK-negative patients, one remote metastases
and three cases of local tumour recurrence were detected. With
respect to age, gender, and distribution of tumour staging, no
significant difference between the CK-positive and CK-negative
patient subgroups was found. The total number of patients for
subgroup analysis was small, but the criteria to draw any firm
conclusions were fulfilled by statistical calculation.
Multivariate analysis
In order to determine independent prognostic factors, a multi-
variate analysis according to the Cox regression model was
performed in the total patient population and in patients with cura-
tive (RO) resection. The analysis showed that curative resection of
the primary tumour (RO-status), the bone marrow status with
detection or lack or CK-positive cells, and the depth of infiltration
of primary tumour (T-category) were independent prognostic
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Table 2 Patient-specific and histopathologic prognosis factors in
multivariate analysis
pT category
pN category
M category
R category
Grading of the primary tumour (G)
Age and gender distribution
Overall survival time
Tumour stage (according to the UICC-classification 1997)
1.0
0.8
0.6
0.4
0.2
0.0
0 6 12 18 24 30 36 42 48 54 60
Months
CK-negative patients
(n = 37)
CK-positive patients
(n = 22)
P < 0.001
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Figure 1 Overall survival for 59 patients with completely resected (RO)
oesophageal cancer according to the presence or absence of CK-positive
cells in their bone marrow.
Table 3 Multivariate analysis of prognostic factors in oesophageal cancer
patients (n = 75)
Prognostic factor P Relative risk
RO category < 0.000001 0.25
Bone marrow state < 0.0019 0.15
T category < 0.0013 0.16factors (Table 3). The bone marrow status and the depth of primary
tumour (T-category) were also relevant prognostic factors in the
multivariate analysis of exclusively curatively resected patients,
after exclusion of RO-status as a prognostic factor.
DISCUSSION
In various clinical studies, the sensitivity and prognostic relevance
of isolated, disseminated epithelial cells in bone marrow of
patients with a solid tumour has been documented (Diel and
Kaufmann, 1996; Heiss et al, 1995; Johnson et al, 1995;
Lindemann et al, 1992; Mass et al 1991; Pantel et al, 1993;
Thorban et al, 1996). But the value of epithelial cells in bone
marrow as an independent prognostic factor has been critically
assessed in a recent meta-analysis (Funke and Schraut, 1998). An
average prevalence of approximately 35% of CK-positive cells in
bone marrow was found for the various types of carcinoma inves-
tigated. Fourteen of the 20 studies analyzed showed, using
univariate analysis, a positive correlation between these cells and a
reduced tumour recurrence-free survival time. However, only five
out of 11 studies confirmed a positive finding in bone marrow as
an independent prognostic factor for a disease-free period. The
total survival time as an independent prognostic factor is shown in
five out of 12 studies using univariate analysis, and in only two
studies in the multivariate analysis. The present study is the first
report of the detection and the evaluation of prognostic value of
epithelial cells in bone marrow of patients with squamous cell
carcinoma of the oesophagus. Our analysis showed that the detec-
tion of epithelial cells in bone marrow of patients with oesophagus
carcinoma has significant prognostic importance. The poor prog-
nosis of CK-positive in comparison to CK-negative patients was
confirmed by the significantly decreased total survival time (P <
0.001). Furthermore, in the multivariate analysis of all prognostic
factors, the detection of CK-positive cells represented an indepen-
dent prognostic factor in addition to the T- and R-category.
The destiny of these epithelial cells in bone marrow can have
various courses. While some cells can become precursors for
skeletal metastases, others leave the bone marrow and can settle
and develope metastases in various other organs. This hypothesis
may explain the very low number of skeletal metastases in CK-
positive patients in the present study, which is in concordance to
other reported studies (Anderson and Lad, 1982; Mandard et al,
1981). Epithelial cells in bone marrow appear to indicate the tran-
sition of the state of tumour disease, which on one hand could
show a general spreading of the primary tumour, but not neces-
sarily a metastasization. In many studies bone marrow is used as
the indicator organ because it is easily accessible and is normally
devoided of epithelial cells. So far, analysis of two aspirates from
both sites of the iliac crest seems to be sufficient to detect about
90% of patients with epithelial cells in bone marrow. Recent
results showed that detection rates based on iliac crest marrow are
underestimated. O’Sullivan et al (1999) found in bone marrow of
the rib in 88% of his patients epithelial cells.
Another important point may be the different results from
immunohistochemistry if polymerase chain reaction (PCR)
methods were employed. Theoretically, the PCR method should be
the most sensitive method to detect epithelial cells in bone marrow
or lymph nodes. Until now it was difficult to establish a respective
approach for screening such patients, because of the tumour
cell heterogeneity. Although such assays are extremely sensitive,
their specifity is limited by the low-level ectopic expression of
cytokeratin mRNA in nonepithelial cells. While such contamina-
tion can be discriminated by the cytologic approach used here, it
cannot be distinguished by RT-PCR.
As previously mentioned, detection of micrometastases is not
only possible in bone marrow but also in lymph nodes, despite
negative conventional histopathologicic findings. A previous
study at our institute with 69 oesophageal cancer patients with
complete resection of the primary tumour, it was shown that with
regard to survival time the detection of micrometastases in cases
of ‘histologically tumour-free’ lymph nodes prognostically corre-
sponded to a lymph node metastasization (Natsugoe et al, 1998).
In 24 of the 69 (34.8%) patients, epithelial cells in bone marrow
were screened during the same observation period. The correlation
of bone marrow status with micrometastases in lymph nodes is
presented in Table 4. A correspondence concerning micrometas-
tases between bone marrow state and lymph node state was found
in 15 (62.5%) patients. Izbickl et al (1997) support the prognostic
importance of micrometastases in lymph nodes of oesophageal
cancer patients with regard to the decreased overall survival and
recurrence-free survival time. In all of the 25 patients of this study
with CK-positive bone marrow status, a positive lymph node
involvement was also found. Furthermore, in 40% of the patients
with CK-negative bone marrow, an immunocytologically positive
lymph node involvement was detected. On the contrary, Glickman
et al, (1999) reported, in 78 oesophageal carcinoma patients, no
correlation between the detection of occult lymph node metastases
and any of the clinical or histopathologic prognostic factors.
Therefore, he proposed no further immunocytologic examination
of lymph nodes in order to improve tumour staging.
The occurrence of CK-positive cells in bone marrow indicates
precise tumour staging with haematogenous dissemination of
malignant cells leading to an increased risk of metastatic relapse.
Thus far, the influence of neoadjuvant therapy on the appearance
and change of CK-positive cells in bone marrow of oesophageal
cancer patients has not been thoroughly investigated. In the course
of the disease all patients died after 2–5 years due to remote metas-
tases inspite of their response to neoadjuvant therapy Herskovic
et al, 1992; Wolfe et al, 1993. That fact raises the question if inad-
equate chemotherapy was given to manage metastatic or even
micrometastatic disease. Previous analyses of micrometastatic
tumour cells in the bone marrow of patients with gastrointestinal
carcinomas indicated that the majority of these cells are in a non-
proliferative state, which explains the relative ineffectiveness of a
systemic chemotherapy (Pantel, 1993). Furthermore, it is unclear
whether CK-positive cells surviving in bone marrow after
RTx/CTx have the same metastatic potential as the cells present
before neoadjuvant therapy. A major objective of future investiga-
tions will be the precise characterization of the phenotype of these
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Table 4 Incidence of CK-positive cells in bone marrow and micrometastasis
of lymph nodes in oesophageal cancer patients (n = 24)
Bone marrow state Micrometastasis of lymph nodes n (%)
Positive Positive 3 (12.5)
Positive Negative 4 (16.5)
Negative Positive 5 (20.8)
Negative Negative 12 (50.0)
Correspondence of bone marrow state and lymp node state in 15 (62.5%)
patientsepithelial cells, e.g. using fluorescence in situ hybridization, in
order to improve the understanding of the oncogene potential of
these cells. The multivariate analysis, first carried out in our popu-
lation of oesophageal cancer patients, underlines that the detection
of these cells represents an independent prognostic factor. Further
investigations regarding the effect of a combined neoadjuvant and
antibody therapy with resection of the primary tumour on these
cells in bone marrow are necessary. As suggested by this study,
immunocytological detection of CK-positive cells might be
helpful for precise preoperative tumour staging and monitoring of
tumour response after neoadjuvant therapy in squamous cell
oesophageal cancer patients.
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